Please ensure Javascript is enabled for purposes of website accessibility

How Biomarin Beat Expectations in Q2

By Keith Speights - Updated Aug 5, 2020 at 7:55AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Two of the biotech's drugs performed especially well in the second quarter.

You won't find many people who would complain about BioMarin Pharmaceutical's (BMRN -0.97%) performance so far this year. The stock has soared 68% since its March low and is now up more than 40% year to date.

BioMarin announced its second-quarter results after the market closed on Tuesday. And it didn't disappoint. Here are the highlights from BioMarin's Q2 update.

Male scientist holding test tube with a test tube rack in front of him

Image source: Getty Images.

By the numbers

BioMarin reported revenue in the second quarter of $429.5 million, up 11% year over year. This result easily topped the consensus Wall Street revenue estimate of $418.6 million.

The company announced a net loss in the second quarter of $29.2 million, or $0.16 per share, based on generally accepted accounting principles (GAAP). However, BioMarin's bottom line improved from the GAAP net loss of $37.4 million, or $0.21 per share, posted in the prior-year period. 

Wall Street is usually more concerned with adjusted non-GAAP earnings, though. BioMarin recorded adjusted net income of $57.4 million, or $0.32 per share. This blew past the average analysts' earnings estimate of $0.16 per share.

Behind the numbers

BioMarin's revenue growth in the second quarter was driven mainly by higher sales of two drugs. Sales of Aldurazyme, which is approved for treating rare genetic disease mucopolysaccharidosis I (MPS I), skyrocketed 457% higher year over year to $32.3 million. Sales for Palynziq, which treats genetic disorder phenylketonuria (PKU), soared 116% to $40.7 million.

Sales for the company's top-selling PDU drug, Kuvan, rose 8% year over year to $122.6 million -- mainly because of a price increase in the U.S. BioMarin's MPS IVA drug Vimizim lost some steam in Q2, with sales falling 5% year over year due to the timing of orders and the negative impact of the COVID-19 pandemic.

Naglazyme ranked as the biotech's worst performer in the second quarter. Sales for the MPS VI drug sank 18% year over year to $81 million. As was the case for Vimizim, Naglazyme's sales declined because of the timing of orders and the pandemic.

BioMarin's GAAP bottom line improved in Q2 in part because of its revenue growth. The company also benefited from a higher income tax benefit than in the prior-year period. Its adjusted earnings rose in the second quarter of 2020 thanks primarily to lower research and development expenses and a higher gross profit.

Looking ahead

BioMarin projects sales of between $1.85 billion and $1.95 billion for full-year 2020, the same as its previous outlook given in April. The company expects GAAP net income will come in between $720 million and $980 million, up from the range of $20 million to $80 million previously announced. 

There are several potential catalysts on the way for the biotech stock in the next several months. An FDA approval decision for Valoctocogene Roxaparvovec in treating severe hemophilia A is expected by Aug. 21. BioMarin expects European approval of the drug by late 2020 or early 2021. In addition, the company awaits European approval for Vosoritide in treating children with bone growth disorder achondroplasia.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends BioMarin Pharmaceutical. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioMarin Pharmaceutical Inc. Stock Quote
BioMarin Pharmaceutical Inc.
BMRN
$95.07 (-0.97%) $0.93

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
389%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.